Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2004

View Archived Issues

TT-232, a somatostatin analogue, demonstrates in vivo antitumor activity

Novel DNA intercalating agent for antitumor therapy described

Allergan plans IND filing for Peplin's topical drug for actinic keratosis

Nanogen to acquire SYN X Pharma

Lundbeck and Merck & Co. to develop and commercialize gaboxadol

Chiesi and 3M to develop Modulite HFA products for North America

MediGene completes enrollment in final phase III trial of Polyphenon E

Eisai reports on progress of global clinical development

Maxim reviews first quarter developments

Praecis achieves primary goal for 2003

Efficacy and safety of efalizumab in the treatment of psoriasis

Improved epithelial chloride transport found with Moli-1901 in cystic fibrosis

Pregabalin reported effective and safe as adjunctive therapy for patients with partial seizures

Hyperleptinemia in lean ZDF rats reduces weight and converts white adipocytes into fat burning cells

Poseidon claims new BK(Ca) channel modulators for respiratory and cardiovascular disorders

New factor Xa/factor VIIa inhibitors covered by Merck KGaA patent

Novel caspase inhibitors discovered by Vertex researchers

New NPY Y5 antagonists and their use reported by Banyu

Pharmacia team prepares and tests new MMP inhibitors

Aventis describes adenosine A1 agonists with potential as antidiabetic agents

New beta3-adrenoceptor agonists and their use in urinary incontinence

Myfortic completes European mutual recognition procedure

Riomet launched in U.S.

New phase II trial studies effects of ALT-711 on endothelial function

Improvement in cognitive function in schizophrenics after switch to ziprasidone

Aeroneb Go Nebulizer available in U.S.

Orphan drug status for Altastaph

IND filing for phase I/II AVENGE trial of EW-A-401

Fast track status for Fibrillex

Third of four phase II trials initiated for PI-88

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.